Prostate-Specific Antigen (PSA) Decline with Apalutamide Therapy is Associated with Longer Survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A Plain Language Summary of the TITAN Study
Future Oncology · 2024
DOI: 10.2217/fon-2023-0649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Simon Chowdhury und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urological Cancer, Guy's, King's & St Thomas' Hospitals, London, UK. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
WHAT IS THIS SUMMARY ABOUT?: This summary describes the results from an additional (or post hoc) analysis of the TITAN study. The TITAN study looked at whether the prostate cancer treatment apalutamide could be used to treat individuals with metastatic castration-sensitive prostate cancer (or mCSPC). A total of 1052 participants with mCSPC were included in the TITAN study. Treatment with apalutamide was compared with treatment with placebo. All participants received androgen deprivation therapy (or ADT), which is a type of hormone therapy that has been part of the main treatment for mCSPC for many years. The results showed that apalutamide plus ADT increased the length of time that participants remained alive compared with placebo plus ADT. Apalutamide plus ADT also controlled the growth of the cancer for a longer length of time compared with placebo plus ADT. Additionally, participants who received apalutamide plus ADT experienced a greater reduction in the blood levels of prostate-specific antigen (or PSA), called a deep PSA decline, compared with those who received placebo plus ADT. An additional (or post hoc) analysis was carried out to understand whether a decrease in blood PSA levels, in response to treatment, was associated with improved outcomes, including longer survival time. WHAT WERE THE RESULTS OF THE ADDITIONAL ANALYSIS?: In participants who received apalutamide plus ADT, a deep PSA decline in response to treatment was associated with longer survival time and improved outcomes. WHAT DO THESE RESULTS MEAN FOR INDIVIDUALS WITH MCSPC?: These results demonstrate that individuals with mCSPC can benefit from treatment with apalutamide plus ADT. The association seen between deep PSA decline and the longer survival time and improved outcomes highlights how PSA measurements can be used to help monitor cancer disease evolution in response to treatment. Monitoring PSA levels will assist doctors and other healthcare professionals to understand how effectively a treatment is working for a patient and to tailor their treatment approach to improve PSA decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urological Cancer, Guy's, King's & St Thomas' Hospitals, London, UK.
- Sarah Cannon Research Institute, London, UK.
- Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden.
- Department of Genitourinary Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
- Department of Urology, Yonsei University College of Medicine & Gangnam Severance Hospital, Seoul, South Korea.
- Department of Urology, Urology of Virginia, Eastern Virginia Medical School, Norfolk, VA, USA.
Zitieren
APA
Chowdhury, S., Bjartell, A., Agarwal, N., Chung, B. H., Given, R. W., Pereira de Santana Gomes, A. J., Merseburger, A. S., Özgüroğlu, M., Soto, Á. J., Uemura, H., Ye, D. W., Brookman-May, S. D., Londhe, A., Bhaumik, A., Mundle, S. D., Larsen, J. S., McCarthy, S. A., & Chi, K. N. (2024). Prostate-Specific Antigen (PSA) Decline with Apalutamide Therapy is Associated with Longer Survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A Plain Language Summary of the TITAN Study. Future Oncology. https://doi.org/10.2217/fon-2023-0649
Vancouver
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, et al. Prostate-Specific Antigen (PSA) Decline with Apalutamide Therapy is Associated with Longer Survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A Plain Language Summary of the TITAN Study. Future Oncology. 2024. doi:10.2217/fon-2023-0649
BibTeX
@article{Chowdhury2024,
author = {Chowdhury, Simon and Bjartell, Anders and Agarwal, Neeraj and Chung, Byung H and Given, Robert W and Pereira de Santana Gomes, Andrea J and Merseburger, Axel S and Özgüroğlu, Mustafa and Soto, Álvaro Juárez and Uemura, Hirotsugu and Ye, Ding-Wei and Brookman-May, Sabine D and Londhe, Anil and Bhaumik, Amitabha and Mundle, Suneel D and Larsen, Julie S and McCarthy, Sharon A and Chi, Kim N},
title = {Prostate-Specific Antigen (PSA) Decline with Apalutamide Therapy is Associated with Longer Survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A Plain Language Summary of the TITAN Study},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-0649}
}
EUVIMED